

Supporting Information

Combination of Epigallocatechin-3-gallate and Silibinin: A Novel Approach for Targeting Both Tumor and Endothelial Cells

Somaye Mirzaaghaei[†], Ali M. Foroughmand^{**†}, Ghasem Saki[‡], Mohammad Shafiei[†]

[†] Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Golestan Blvd, Ahvaz-Iran.

[‡] Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz-Iran.

*Corresponding author:

Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Golestan Blvd, Ahvaz-Iran.

Tel: +986133367008

Fax: +986133332618

E-mail address: aliforough12@yahoo.com

Supporting information

Figure S1. Decreased cell viability of HUVEC, A549 and HDF in a dose dependent manner in response to EGCG and Silibinin. Relative cell viability of, A) HUVEC, B) A549, and C)HDF cells, in response to silibinin (100, 125 μ M) or EGCG (100, 125 μ g/mL), in compare with control, in 24 hrs. Values represent mean \pm SEM of at least three triplicate replicates (Unequal letters indicate significant difference with $P < 0.05$).

